Retrospective comparison between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma.
OBJECTIVE
To compare the therapeutic effects between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma (NHL).


METHODS
Of 79 NHL patients, 40 received CHOP-PVP and 39 received CHOP protocol. Kaplan-Meier method was used for survival rate and Cox regression model for prognostic factors.


RESULTS
The complete remission rate and overall response rate were 57.5% (23/40) and 87.5% (35/40) in CHOP-PVP group and they were 33.3% (13/39) and 69.2% (27/39) in CHOP group. There was a significant difference (P < 0.05) in the complete remission rate and overall response rate between the two groups. The main toxicity was myelosuppression. The leukocytopenia rate was 82.5% in CHOP-PVP group and 71.8% in CHOP group (P > 0.05) with no fatality in either group.


CONCLUSIONS
CHOP-PVP protocol may be more effective for non-Hodgkin's lymphoma than CHOP protocol without increasing toxicity.
Gan
Huizhu
H
Department of Hematology and Oncology, Third Medical College, Jilin University, Changchun 130031, China.
Zhang
Fengchun
F
Lin
Yumei
Y
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone